ClinicalTrials.gov Identifier: NCT04232969.
| Study name | Exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease (Exenatide‐PD3) |
| Methods | Randomised, double‐blind, parallel‐group, placebo‐controlled, phase 3 trial |
| Participants | Newly diagnosed patients |
| Interventions |
Intervention: Exenatide extended release 2mg (Bydureon) once weekly for 96 weeks Comparison: Placebo once weekly for 96 weeks |
| Outcomes | MDS‐UPDRS part 3 motor sub‐score in the practically defined OFF medication |
| Starting date | January 2020 |
| Contact information | t.foltynie@ucl.ac.uk |
| Notes |